Showing 8111-8120 of 9806 results for "".
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab
- Remembering a Legend: Vic A Narurkar, MDhttps://practicaldermatology.com/news/remembering-a-legend-vic-a-narurkar-md/2459921/The dermatology community lost a true rock star with the sudden passing of Vic A Narurkar MD, FAAD in late January. Loved by so many, Dr. Narurkar was the Founder of the Bay Area Laser Institute in San Francisco and a past president of the American Society of Cosmetic Derma
- Merz and Christie Brinkley Partner to Launch “Milestones of Me” Campaignhttps://practicaldermatology.com/news/merz-and-christie-brinkley-partner-to-launch-milestones-of-me-campaign/2459922/Merz Americas is partnering with supermodel, actress, and entrepreneur, Christie Brinkley, to launch its “Milestones of Me” campaign, which encourages women to celebrate the moments, big or small, that have made them who they are today. The campaign, which kicks off in honor of Christ
- Keloids May Up Breast Cancer Riskhttps://practicaldermatology.com/news/keloids-may-up-breast-cancer-risk/2459925/Keloids may be associated with an increased risk breast cancer, particularly among African Americans, a new study suggests. The research team hypothesized African American women with a history of keloids would reflect a population of breast cancer patients with aggressive tumors and poor
- Dermatologists Call for Changes to Off-label Coverage Decisionshttps://practicaldermatology.com/news/dermatologists-call-for-changes-to-off-label-coverage-decisions/2459926/Dermatologists report major inconsistencies in Medicare Reimbursement Policy for off-label prescriptions and are now calling for an appeal process for cases where coverage is denied. Researchers from several institutions, including the Perelman School of Medicine at the University of Pennsylvania